These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 36915718)

  • 1. Propensity score matching analysis of efficacy of drug-eluting beads (DEB)-TACE loaded with different drugs in the treatment of hepatocellular carcinoma.
    Yang L; Wang H; Li S; Gan G; Deng W; Chang Y; Zhang L
    Am J Transl Res; 2023; 15(2):1526-1532. PubMed ID: 36915718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of raltitrexed-eluting CalliSpheres
    Sun Z; Jiao D; Fang Y; Liu Y; Xu K; Zhang C; Huang Y; Han X
    Ther Adv Med Oncol; 2024; 16():17588359241229661. PubMed ID: 38362379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of DEB-TACE and cTACE for the initial treatment of unresectable hepatocellular carcinoma beyond up-to-seven criteria: A single-center propensity score matching analysis.
    Shi Q; Liu J; Li T; Zhou C; Wang Y; Huang S; Yang C; Chen Y; Xiong B
    Clin Res Hepatol Gastroenterol; 2022 May; 46(5):101893. PubMed ID: 35247625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CalliSpheres drug-eluting beads versus lipiodol transarterial chemoembolization in the treatment of hepatocellular carcinoma: a short-term efficacy and safety study.
    Wu B; Zhou J; Ling G; Zhu D; Long Q
    World J Surg Oncol; 2018 Mar; 16(1):69. PubMed ID: 29587773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transarterial chemoembolization using drug-eluting beads versus lipiodol in the treatment of unresectable hepatocellular carcinoma: propensity score matching.
    Cao G; Gu J; Zhang H; Ji W; Zhu D; Bao Y; Asi H; Ren W
    J Gastrointest Oncol; 2024 Jun; 15(3):1101-1111. PubMed ID: 38989437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of initial tumor responses to transarterial bland embolization and drug-eluting beads-transarterial chemoembolization in the management of hepatocellular carcinoma: a propensity-score matching analysis.
    Guo J; Wang W; Zhang Y; Xu L; Kong J
    J Gastrointest Oncol; 2021 Aug; 12(4):1838-1850. PubMed ID: 34532132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of camrelizumab plus transarterial chemoembolization on massive hepatocellular carcinoma.
    Zhang S; Zhao Y; He L; Bo C; An Y; Li N; Ma W; Guo Y; Guo Y; Zhang C
    Clin Res Hepatol Gastroenterol; 2022 Apr; 46(4):101851. PubMed ID: 34923180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preliminary outcomes of DEB-TACE loaded with raltitrexed in the treatment of unresectable or recurrent hepatocellular carcinoma.
    Bi Y; Wang Y; Zhang W; Lu H; Ren J; Han X
    Cancer Imaging; 2023 Feb; 23(1):19. PubMed ID: 36814327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of Drug-Eluting Beads Transarterial Chemoembolization by CalliSpheres
    Sun J; Zhou G; Xie X; Gu W; Huang J; Zhu D; Hu W; Hou Q; Shi C; Li T; Zhang X; Ji W; Ying S; Peng Z; Zhou J; Yu Z; Ji J; Du H; Guo X; Fang J; Han J; Xu H; Sun Z; Yu W; Shao G; Wu X; Hu H; Li L; Zheng J; Luo J; Chen Y; Cao G; Hu T
    Oncol Res; 2020 Feb; 28(1):75-94. PubMed ID: 31558180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Outcomes of Drug-Eluting Bead Transarterial Chemoembolization Loaded with Raltitrexed for the Treatment of Unresectable or Recurrent Hepatocellular Carcinoma.
    Bi Y; Jiao D; Ren J; Han X
    Can J Gastroenterol Hepatol; 2022; 2022():2602121. PubMed ID: 36051250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug-eluting bead transarterial chemoembolization is efficient and well-tolerated in treating elderly Chinese hepatocellular carcinoma patients.
    Zhou Y
    Int J Clin Exp Pathol; 2018; 11(10):4867-4878. PubMed ID: 31949562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conventional versus drug-eluting beads chemoembolization for infiltrative hepatocellular carcinoma: a comparison of efficacy and safety.
    Zhang ZS; Li HZ; Ma C; Xiao YD
    BMC Cancer; 2019 Nov; 19(1):1162. PubMed ID: 31783814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The short-term efficacy of DEB-TACE loaded with epirubicin and raltitrexed in the treatment of intermediate and advanced primary hepatocellular carcinoma.
    Yang X; Li H; Liu J; Du C; He T; Luo X; Liao Q; Yu N
    Am J Transl Res; 2021; 13(8):9562-9569. PubMed ID: 34540079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pirarubicin-loaded CalliSpheres® drug-eluting beads for the treatment of patients with stage III-IV lung cancer.
    Bi Y; Shi X; Yi M; Han X; Ren J
    Acta Radiol; 2022 Mar; 63(3):311-318. PubMed ID: 33615822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy, safety, and prognostic factors of drug-eluting beads transarterial chemoembolization using CalliSpheres in treating huge hepatocellular carcinoma patients.
    Wang Z; Mu K; Lv Y; Zhao L; Li B; Hao Y; Wang N
    Ir J Med Sci; 2022 Dec; 191(6):2493-2499. PubMed ID: 35064533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival and Outcome in Patients Receiving Drug-Eluting Beads Transarterial Chemoembolization for Large Hepatocellular Carcinoma (>5 cm).
    Mukund A; Bhardwaj K; Choudhury A; Sarin SK
    J Clin Exp Hepatol; 2021; 11(6):674-681. PubMed ID: 34866846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transarterial chemoembolization combined with apatinib with or without PD-1 inhibitors in BCLC stage C hepatocellular carcinoma: A multicenter retrospective study.
    Xia WL; Zhao XH; Guo Y; Cao GS; Wu G; Fan WJ; Yao QJ; Xu SJ; Guo CY; Hu HT; Li HL
    Front Oncol; 2022; 12():961394. PubMed ID: 36249011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive predictive factors for CalliSpheres® microspheres (CSM) drug-eluting bead-transarterial chemoembolization and conventional transarterial chemoembolization on treatment response and survival in hepatocellular carcinoma patients.
    Chen C; Qiu H; Yao Y; Zhang Z; Ma C; Ma Y; Zhao C; Xiang H; Zhao H; Zheng C; Xiong B; Li H; Long Q; Zhou J; Luo C; Hu H
    Clin Res Hepatol Gastroenterol; 2021 Mar; 45(2):101460. PubMed ID: 32593695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment efficacy and safety of drug-eluting beads transarterial chemoembolization versus conventional transarterial chemoembolization in hepatocellular carcinoma patients with arterioportal fistula.
    Cai L; Li H; Guo J; Zhao W; Duan Y; Hou X; Cheng L; Du H; Shao X; Diao Z; Hao Y; Zheng X; Li C; Li W
    Cancer Biol Ther; 2022 Dec; 23(1):89-95. PubMed ID: 35230928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of lipiodol infusion and drug-eluting beads transarterial chemoembolization of hepatocellular carcinoma in a real-life setting.
    Karalli A; Teiler J; Haji M; Seth E; Brismar TB; Wahlin S; Axelsson R; Stål P
    Scand J Gastroenterol; 2019 Jul; 54(7):905-912. PubMed ID: 31287338
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.